MicroRNA expression profiling in bladder cancer: The challenge of next-generation sequencing in tissues and biofluids

International Journal of Cancer

Volumn 138, Issue 10, 2016, Pages 2334-2345

  Matullo, Giuseppe ^a,b   Naccarati, Alessio ^a   Pardini, Barbara ^a,b  

^a Human Genetics Foundation   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

biofluids; bladder cancer; expression profiling; microRNA; next generation sequencing

Indexed keywords

MICRORNA; MICRORNA 1; MICRORNA 100; MICRORNA 101; MICRORNA 125B; MICRORNA 143; MICRORNA 145; MICRORNA 16; MICRORNA 205; MICRORNA 21; MICRORNA 221; TRANSCRIPTOME; TUMOR MARKER;

BLADDER CANCER; BODY FLUID; CANCER DIAGNOSIS; CANCER PROGNOSIS; EXOSOME; GENE EXPRESSION PROFILING; HUMAN; MEMBRANE MICROPARTICLE; MUSCLE INVASIVE BLADDER CANCER; NEXT GENERATION SEQUENCING; NON INVASIVE MEASUREMENT; NON MUSCLE INVASIVE BLADDER CANCER; PLASMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA ISOLATION; RNA SEQUENCE; SERUM; TUMOR RECURRENCE; URINE; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; URINARY BLADDER NEOPLASMS;

BIOMARKERS, TUMOR; BODY FLUIDS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICRORNAS; TRANSCRIPTOME; URINARY BLADDER NEOPLASMS;

EID: 84959887679     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29895     Document Type: Review

References (104)

1. Ferlay J, Soerjomataram I, Dikshit R, et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386.
2. Siegel R, Naishadham D, Jemal A., Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
3. Chavan S, Bray F, Lortet-Tieulent J, et al., International variations in bladder cancer incidence and mortality. Eur Urol 2014; 66: 59-73.
4. Sanguedolce F, Bufo P, Carrieri G, et al., Predictive markers in bladder cancer: do we have molecular markers ready for clinical use? Crit Rev Clin Lab Sci 2014; 51: 291-304.
5. Knowles MA, Hurst CD., Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 2015; 15: 25-41.
6. Urist MJ, Di Como CJ, Lu ML, et al., Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002; 161: 1199-206.
7. Junttila TT, Laato M, Vahlberg T, et al., Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancr Res 2003; : 5346-57.
8. Habuchi T, Marberger M, Droller MJ, et al., Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 2005; 66: 64-74.
9. Dudek AM, Grotenhuis AJ, Vermeulen SH, et al., Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms? Int J Mol Sci 2013; 14: 12346-66.
10. Sacerdote C, Guarrera S, Ricceri F, et al., Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy. Int J Cancer 2013; 133: 2004-9.
11. Stern MC, Lin J, Figueroa JD, et al., Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. Cancer Res 2009; 69: 6857-64.
12. Teo MT, Dyrskjot L, Nsengimana J, et al., Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer. Ann Oncol 2014; 25: 877-83.
13. Russo A, Modica F, Guarrera S, et al., Shorter leukocyte telomere length is independently associated with poor survival in patients with bladder cancer. Cancer Epidemiol Biomarkers Prev 2014; 23: 2439-46.
14. Kaufman DS, Shipley WU, Feldman AS., Bladder cancer. Lancet 2009; 374: 239-49.
15. Habuchi T., Origin of multifocal carcinomas of the bladder and upper urinary tract: molecular analysis and clinical implications. Int J Urol 2005; 12: 709-16.
16. Dimashkieh H, Wolff DJ, Smith TM, et al., Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol 2013; 121: 591-7.
17. van Rhijn BW, van der Poel HG, van der Kwast TH., Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005; 47: 736-48.
18. Wild PJ, Fuchs T, Stoehr R, et al., Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis. Cancer Epidemiol Biomarkers Prev 2009; 18: 1798-806.
19. Avritscher EB, Cooksley CD, Grossman HB, et al., Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006; 68: 549-53.
20. Martens-Uzunova ES, Olvedy M, Jenster G., Beyond microRNA-novel RNAs derived from small non-coding RNA and their implication in cancer. Cancer Lett 2013; 340: 201-11.
21. Dietrich D, Meller S, Uhl B, et al., Nucleic acid-based tissue biomarkers of urologic malignancies. Crit Rev Clin Lab Sci 2014; 51: 173-99.
22. Ambros V., The functions of animal microRNAs. Nature 2004; 431: 350-5.
23. Zhou H, Rigoutsos I., MiR-103a-3p targets the 5' UTR of GPRC5A in pancreatic cells. RNA 2014; 20: 1431-9.
24. Leung AK, Young AG, Bhutkar A, et al., Genome-wide identification of Ago2 binding sites from mouse embryonic stem cells with and without mature microRNAs. Nat Struct Mol Biol 2011; 18: 237-44.
25. Tay Y, Kats L, Salmena L, et al., Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 2011; 147: 344-57.
26. Gu TJ, Yi X, Zhao XW, et al., Alu-directed transcriptional regulation of some novel miRNAs. BMC Genomics 2009; 10: 563.
27. Hansen TB, Jensen TI, Clausen BH, et al., Natural RNA circles function as efficient microRNA sponges. Nature 2013; 495: 384-8.
28. Tilki D, Burger M, Dalbagni G, et al., Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 2011; 60: 484-92.
29. Cortez MA, Bueso-Ramos C, Ferdin J, et al., MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011; 8: 467-77.
30. Negrini M, Nicoloso MS, Calin GA., MicroRNAs and cancer-new paradigms in molecular oncology. Curr Opin Cell Biol 2009; 21: 470-9.
31. Xue B, He L., An expanding universe of the non-coding genome in cancer biology. Carcinogenesis 2014; 35: 1209-16.
32. Hui A, How C, Ito E, et al., Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. BMC Cancer 2011; 11: 500.
33. Nana-Sinkam SP, Croce CM., Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 2013; 93: 98-104.
34. Yoshino H, Seki N, Itesako T, et al., Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol 2013; 10: 396-404.
35. Bartel DP., MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33.
36. Costa V, Angelini C, De Feis I, et al., Uncovering the complexity of transcriptomes with RNA-Seq. J Biomed Biotechnol 2010; 2010: 853916.
37. Shendure J., The beginning of the end for microarrays? Nat Methods 2008; 5: 585.
38. Costa V, Aprile M, Esposito R, et al., RNA-Seq and human complex diseases: recent accomplishments and future perspectives. Eur J Hum Genet 2013; 21: 134-42.
39. Gottardo F, Liu CG, Ferracin M, et al., Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007; 25: 387-92.
40. Wiklund ED, Bramsen JB, Hulf T, et al., Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011; 128: 1327-34.
41. Yoshino H, Chiyomaru T, Enokida H, et al., The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer 2011; 104: 808-18.
42. Huang L, Luo J, Cai Q, et al., MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer 2011; 128: 1758-69.
43. Noguchi S, Mori T, Hoshino Y, et al., MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett 2011; 307: 211-20.
44. Lin T, Dong W, Huang J, et al., MicroRNA-143 as a tumor suppressor for bladder cancer. J Urol 2009; 181: 1372-80.
45. Noguchi S, Yasui Y, Iwasaki J, et al., Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett 2013; 328: 353-61.
46. Friedman JM, Liang G, Liu CC, et al., The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 2009; 69: 2623-9.
47. Guancial EA, Bellmunt J, Yeh S, et al., The evolving understanding of microRNA in bladder cancer. Urol Oncol 2014; 32: 41.e31-40.
48. Zabolotneva AA, Zhavoronkov AA, Shegay PV, et al., A systematic experimental evaluation of microRNA markers of human bladder cancer. Front Genet 2013; 4: 247.
49. Schaefer A, Stephan C, Busch J, et al., Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol 2010; 7: 286-97.
50. Han Y, Chen J, Zhao X, et al., MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One 2011; 6: e18286.
51. Chen YH, Wang SQ, Wu XL, et al., Characterization of microRNAs expression profiling in one group of Chinese urothelial cell carcinoma identified by Solexa sequencing. Urol Oncol 2013; 31: 219-27.
52. Zhu J, Jiang Z, Gao F, et al., A systematic analysis on DNA methylation and the expression of both mRNA and microRNA in bladder cancer. PLoS One 2011; 6: e28223.
53. Li X, Chen J, Hu X, et al., Comparative mRNA and microRNA expression profiling of three genitourinary cancers reveals common hallmarks and cancer-specific molecular events. PLoS One 2011; 6: e22570.
54. Itesako T, Seki N, Yoshino H, et al., The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster. PLoS One 2014; 9: e84311.
55. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507: 315-22.
56. Ralla B, Stephan C, Meller S, et al., Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. Crit Rev Clin Lab Sci 2014; 51: 200-31.
57. Adam L, Wszolek MF, Liu CG, et al., Plasma microRNA profiles for bladder cancer detection. Urol Oncol 2013; 31: 1701.
58. Spornraft M, Kirchner B, Haase B, et al., Optimization of extraction of circulating RNAs from plasma-enabling small RNA sequencing. PLoS One 2014; 9: e107259.
59. Ellinger J, Muller SC, Dietrich D., Epigenetic biomarkers in the blood of patients with urological malignancies. Exp Rev Mol Diagn 2015; 15: 505-16.
60. Sapre N, Anderson PD, Costello AJ, et al., Gene-based urinary biomarkers for bladder cancer: an unfulfilled promise? Urol Oncol 2014; 32: 48.e9-17.
61. Mlcochova H, Hezova R, Stanik M, et al., Urine microRNAs as potential noninvasive biomarkers in urologic cancers. Urol Oncol 2014; 32: 41.e1-9.
62. Valadi H, Ekstrom K, Bossios A, et al., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 6549:
63. Ladewig E, Okamura K, Flynt AS, et al., Discovery of hundreds of mirtrons in mouse and human small RNA data. Genome Res 2012; 22: 1634-45.
64. Meiri E, Levy A, Benjamin H, et al., Discovery of microRNAs and other small RNAs in solid tumors. Nucleic Acids Res 2010; 38: 6234-46.
65. Jima DD, Zhang J, Jacobs C, et al., Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood 2010; 116: e118-e127.
66. Ulahannan D, Kovac MB, Mulholland PJ, et al., Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. Br J Cancer 2013; 109: 827-35.
67. Friedlander MR, Lizano E, Houben AJ, et al., Evidence for the biogenesis of more than 1,000 novel human microRNAs. Genome Biol 2014; 15: R57.
68. Londin E, Loher P, Telonis AG, et al., Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc Natl Acad Sci USA 2015; 112: E1106-E1115.
69. Tetu B., Diagnosis of urothelial carcinoma from urine. Mod Pathol 2009; 22 Suppl 2: S53-S59.
70. Tzimagiorgis G, Michailidou EZ, Kritis A, et al., Recovering circulating extracellular or cell-free RNA from bodily fluids. Cancer Epidemiol 2011; 35: 580-9.
71. Turchinovich A, Weiz L, Burwinkel B., Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci 2012; 37: 460-5.
72. Garcia-Olmo DC, Garcia-Olmo D., Biological role of cell-free nucleic acids in cancer: the theory of genometastasis. Crit Rev Oncog 2013; 18: 153-61.
73. Hessvik NP, Sandvig K, Llorente A., Exosomal miRNAs as biomarkers for prostate cancer. Front Genet 2013; 4: 36.
74. Link A, Balaguer F, Shen Y, et al., Fecal microRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 2010; 19: 1766-74.
75. Liu AM, Yao TJ, Wang W, et al., Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012; 2: e000825.
76. Mitchell PS, Parkin RK, Kroh EM, et al., Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-18.
77. Weber JA, Baxter DH, Zhang S, et al., The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-41.
78. Corcoran C, Friel AM, Duffy MJ, et al., Intracellular and extracellular microRNAs in breast cancer. Clin Chem 2011; 57: 18-32.
79. Barupal JK, Saini AK, Chand T, et al., ExcellmiRDB for translational genomics: a curated online resource for extracellular microRNAs. Omics 2015; 19: 24-30.
80. Mathivanan S, Simpson RJ., ExoCarta: a compendium of exosomal proteins and RNA. Proteomics 2009; 9: 4997-5000.
81. Russo F, Di Bella S, Nigita G, et al., miRandola: extracellular circulating microRNAs database. PLoS One 2012; 7: e47786.
82. Wang K, Yuan Y, Cho JH, et al., Comparing the MicroRNA spectrum between serum and plasma. PLoS One 2012; 7: e41561.
83. Kroh EM, Parkin RK, Mitchell PS, et al., Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010; 50: 298-301.
84. Kirschner MB, Edelman JJ, Kao SC, et al., The impact of hemolysis on cell-free microRNA biomarkers. Front Genet 2013; 4: 94.
85. Kirschner MB, van Zandwijk N, Reid G., Cell-free microRNAs: potential biomarkers in need of standardized reporting. Front Genet 2013; 4: 56.
86. Bustin SA, Benes V, Garson JA, et al., The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55: 611-22.
87. Jiang X, Du L, Wang L, et al., Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int J Cancer 2015; 136: 854-62.
88. Hanke M, Hoefig K, Merz H, et al., A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2010; 28: 655-61.
89. Peng X, Wood CL, Blalock EM, et al., Statistical implications of pooling RNA samples for microarray experiments. BMC Bioinformatics 2003; 4: 26.
90. Moldovan L, Batte KE, Trgovcich J, et al., Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med 2014; 18: 371-90.
91. Huang X, Yuan T, Tschannen M, et al., Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics 2013; 14: 319.
92. Wang G, Kwan BC, Lai FM, et al., Urinary miR-21, miR-29, and miR-93: novel biomarkers of fibrosis. Am J Nephrol 2012; 36: 412-18.
93. Vickers KC, Remaley AT., Lipid-based carriers of microRNAs and intercellular communication. Curr Opin Lipidol 2012; 23: 91-7.
94. Cheng L, Sun X, Scicluna BJ, et al., Characterization and deep sequencing analysis of exosomal and non-exosomal miRNA in human urine. Kidney Int 2014; 86: 433-44.
95. Real FX, Boutros PC, Malats N., Next-generation sequencing of urologic cancers: next is now. Eur Urol 2014; 66: 4-7.
96. Mestdagh P, Hartmann N, Baeriswyl L, et al., Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods 2014; 11: 809-15.
97. Tam S, de Borja R, Tsao MS, et al., Robust global microRNA expression profiling using next-generation sequencing technologies. Lab Invest 2014; 94: 350-8.
98. Guo Y, Zhao S, Su PF, et al., Statistical strategies for microRNAseq batch effect reduction. Transl Cancer Res 2014; 3: 260-5.
99. Tam S, Tsao MS, McPherson JD., Optimization of miRNA-seq data preprocessing. Brief Bioinform 2015; 1-14.
100. Sorefan K, Pais H, Hall AE, et al., Reducing ligation bias of small RNAs in libraries for next generation sequencing. Silence 2012; 3: 4.
101. Lopez JP, Diallo A, Cruceanu C, et al., Biomarker discovery: quantification of microRNAs and other small non-coding RNAs using next generation sequencing. BMC Med Genomics 2015; 8: 35.
102. Karreth FA, Pandolfi PP., ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov 2013; 3: 1113-21.
103. Poliseno L, Pandolfi PP., PTEN ceRNA networks in human cancer. Methods 2015; 77-78: 41-50.
104. Tay Y, Rinn J, Pandolfi PP., The multilayered complexity of ceRNA crosstalk and competition. Nature 2014; 505: 344-52.